MSH2 and breast cancer: In agreement with results from BRCA1 studies, showing that a splice variant resulting in 70–80% expression of a non-functional allele does not result in an increased breast cancer risk [90], data from MSH2 suggest that >70% of non-functional transcript isoforms should be present before the variant can be classified as pathogenic [51,74].